Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of PF-07321332 + ritonavir versus placebo in high-risk nonhospitalized adults with COVID-19
2021-002895-38Phase 2Active
- Sponsor
- Pfizer
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing PF-07321332 + ritonavir with Placebo (2 arms). Primary endpoint: COVID-19-related hospitalization or death through Day 28. Started Jul 2021; status: active.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002895-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002895-38.